Treating osteoporosis

Gupta, Akhil; March, Lyn

doi:10.18773/austprescr.2016.028

Cited by 26 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Использование оральных бисфосфонатов ограничивается их побочны-ми эффектами при почечной недостаточности. Эрозив-но-язвенные поражения слизистой оболочки желудоч-но-кишечного тракта и нарушения функции пищевода (стриктура, ахалазия), а также неспособность оставать-ся в вертикальном положении в течение 30 мин после приема препарата являются абсолютными противопо-казаниями к их приему [39].…”

Section: материалы и методыunclassified

“…Рекомендуемый режим терапии пероральными бисфосфонатами составляет 5 лет, а внутривенными -менее 3 лет [39,41,42]. В клинических рекомендациях 2013 г. по лечению патологических переломов шейки бедренной кости, возникших на фоне системного ОП, предлагается следующий режим применения бисфос-фонатов в зависимости от показателей кальция кро-ви [43] (табл.…”

Section: материалы и методыunclassified

See 1 more Smart Citation

A Multidisciplinary Approach in the Treatment of Fractures of the Proximal Femur on the Background of Senile Osteoporosis

Загородний¹,

Volná²,

Панфилов³

2016

Klinicist

View full text Add to dashboard Cite

show abstract

Section: материалы и методыunclassified

A Multidisciplinary Approach in the Treatment of Fractures of the Proximal Femur on the Background of Senile Osteoporosis

Загородний¹,

Volná²,

Панфилов³

2016

Klinicist

View full text Add to dashboard Cite

show abstract

“…Использование оральных бисфосфонатов ограничивается их побочными эффектами при почечной недостаточности, а также рядом ограничений со стороны желудочно-кишечного тракта. Так, дисфагия, ахалазия или неспособность оставаться в вертикальном положении в течение 30 мин после приема препарата являются абсолютными противопоказаниями к их приему [38].…”

Section: рис 1 критерии диагностики остеопороза по возunclassified

“…Рекомендуемый режим терапии пероральными бисфосфонатами составляет 5 лет, а внутривенными -менее 3 лет [27,38,50]. В клинических рекомендациях 2013 г. по лечению патологических переломов шейки бедренной кости, возникших на фоне системного остеопороза [15], предложен режим применения бисфосфонатов в зависимости от исходных показателей Ca крови (рис.…”

Section: рис 1 критерии диагностики остеопороза по возunclassified

Clinical Management of Patients Older than 75 Years of Age With Fractures of the Proximal Femur

Загородний¹,

Volná²,

Панфилов³

2016

Rossijskij osteopaticheskij zhurnal

View full text Add to dashboard Cite

This paper presents a review of publications dedicated to the complex clinical management of patients older than 75 years of age who have had fractures of the proximal femur and presented signs of osteoporosis. Descriptive and analytical methods were used in the research. The work with the publications was performed by entering the relevant MeSH terms and subheadings in the search systems of databases. The study found that most researchers think that this problem still needs to be studied in the context of the search for effective clinical management strategies, including the surgical treatment as early as possible and the prescription of medications which inﬂuence bone remodeling mechanisms.

show abstract

“…Strontium ranelate has been reported to both increase markers of bone formation and decrease markers of bone resorption in vitro [13] ; however, there is no in vivo evidence to support its bone anabolic efficacy [14,15] . Although bisphosphonates (Alendronate) and an antibody to RANKL (Denosumab) can increase bone mass by shutting down cells known as osteoclasts, they also hinder the creation of new bone [16,17] . Nevertheless, a combination of teriparatide and denosumab can increase bone mineral density more efficaciously than monotherapy with either agent, especially in postmenopausal women with osteoporosis [18,19] .…”

Section: Introductionmentioning

confidence: 99%

Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects

Shen

Cui

et al. 2017

Acta Pharmacol Sin

View full text Add to dashboard Cite

Osteoporotic treatments have largely depended on antiresorptive or anabolic drugs; but the former also suppresses new bone formation, and the latter only includes human parathyroid hormone. There is no drug that has a dual effect to inhibit bone resorption and to stimulate bone formation simultaneously. Here, we report a small molecule, a quinoxaline derivative of oleanolic acid (QOA-8a) that plays such dual roles in osteoblasts and osteoclasts in the treatment of osteoporosis. Osteoclast differentiation was induced by incubation of primary mouse bone marrow-derived macrophages in the presence of RANKL and M-CSF, treatment with QOA-8a dose-dependently inhibited the osteoclast formation with an IC value of 0.098 μmol/L. QOA-8a also directly acted on osteoblasts, and stimulated new bone formation in murine calvarial bones in vitro and in vivo. In an OVX rat model, administration of QOA-8a (1, 5 mg·kg·d, po) for 16 weeks effectively prevented OVX-induced bone loss, accompanied by decreased serum levels of the bone resorption marker CTX-1 and increased serum levels of osteoblast marker N-MID-OT. Meaningfully, our preliminary study revealed that QOA-8a down-regulated the ERK1/2 signal in osteoclasts and up-regulated the signal in osteoblasts. QOA-8a showed dual functions in both animal and human osteoclastogenesis and osteoblastogenesis. Our results demonstrate that QOA-8a might serve as a lead compound with a dual function of bone anabolic and anti-resorptive effects in the development of anti-osteoporosis agents.

show abstract

Treating osteoporosis

Cited by 26 publications

References 36 publications

A Multidisciplinary Approach in the Treatment of Fractures of the Proximal Femur on the Background of Senile Osteoporosis

A Multidisciplinary Approach in the Treatment of Fractures of the Proximal Femur on the Background of Senile Osteoporosis

Clinical Management of Patients Older than 75 Years of Age With Fractures of the Proximal Femur

Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects

Contact Info

Product

Resources

About